New Zealand markets close in 2 hours 12 minutes
  • NZX 50

    10,921.39
    +59.05 (+0.54%)
     
  • NZD/USD

    0.6217
    +0.0005 (+0.07%)
     
  • NZD/EUR

    0.5955
    +0.0001 (+0.01%)
     
  • ALL ORDS

    6,819.70
    +22.80 (+0.34%)
     
  • ASX 200

    6,632.40
    +19.80 (+0.30%)
     
  • OIL

    110.56
    +2.13 (+1.96%)
     
  • GOLD

    1,810.90
    +9.40 (+0.52%)
     
  • NASDAQ

    11,585.68
    +81.98 (+0.71%)
     
  • FTSE

    7,232.65
    +64.00 (+0.89%)
     
  • Dow Jones

    31,097.26
    +321.86 (+1.05%)
     
  • DAX

    12,773.38
    -39.65 (-0.31%)
     
  • Hang Seng

    21,984.41
    +154.06 (+0.71%)
     
  • NIKKEI 225

    26,364.51
    +210.70 (+0.81%)
     
  • NZD/JPY

    84.6000
    +0.3610 (+0.43%)
     

Turning Point Therapeutics to Participate in Upcoming Investor Conferences

·2-min read
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc.

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced that President and CEO Athena Countouriotis, M.D., will participate in the Jefferies Healthcare Conference on June 8 and the 43rd Annual Goldman Sachs Healthcare Conference on June 14.

Dr. Countouriotis is scheduled to present a company overview in New York on June 8 at 11 a.m. ET and scheduled to participate in a fireside chat on June 14 in Rancho Palo Verdes, California at 1 p.m. ET.

Both sessions will be accessible via webcast through links that will be posted to the Investors page of www.tptherapeutics.com.

About Turning Point Therapeutics Inc.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes elzovantinib, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; TPX-0131, a next-generation ALK inhibitor, which is being studied in a Phase 1/2 trial of previously treated patients with ALK-positive advanced or metastatic non-small cell lung cancer; and TPX-4589 (LM-302), a novel ADC targeting Claudin18.2 which is being studied in a Phase 1 study in gastrointestinal cancers. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.

Contact:
Adam D. Levy, PhD., MBA
ir@tptherapeutics.com
858-867-6366


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting